MLYS Q2 2025 Earnings — Mineralys Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

MLYSMineralys Therapeutics, Inc.

$2B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$47M

Net Income

-$43M

EPS (Diluted)

$-0.66

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$30M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$336M

Total Liabilities

$22M

Stockholders' Equity

$314M

Cash & Equivalents

$102M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$47M	-$45M	-3.5%
Net Income	-$43M	-$41M	-5.5%